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We followed a population-based cohort of 5696 women, 32–38 years of age, by registry linkage with cytology and pathology
registries during a mean follow-up time of 4.1 years to assess the importance for CIN2þ development of type-specific HPV DNA
positivity at baseline. HPV 16, 31 and 33 conveyed the highest risks and were responsible for 33.1, 18.3 and 7.7% of CIN2þ cases,
respectively. Women infected with HPV 18, 35, 39, 45, 51, 52, 56, 58, 59 and 66 had significantly lower risks of CIN2þ than women
infected with HPV 16. After adjustment for infection with other HPV types, HPV types 35, 45, 59 and 66 had no detectable
association with CIN2þ. In summary, the different HPV types found in cervical cancer show distinctly different CIN2þ risks, with
high risks being restricted to HPV 16 and its close relatives HPV 31 and HPV 33.
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Infection with ‘high-risk’ types of HPV is the major cause of
cervical cancer, and the distribution of different HPV types in
cancer tissue has been extensively analysed (Walboomers et al,
1999; Bosch et al, 2002; Munoz et al, 2003). Fifteen HPV types that
infect the genital mucosa have been proposed as ‘high-risk’ HPV
types as they have been found more often in cervical cancers than
among healthy subjects (Munoz et al, 2003). Data on the HPV
type-specific risk of cervical neoplasia has hitherto mostly been
based on cross-sectional case–control studies (Bosch et al, 1995;
Clifford et al, 2003; Munoz et al, 2003). Case–control studies are
sensitive to several biases, notably selection bias, differential
sampling bias and other reverse causality biases. Absolute risks
and population attributable proportions for each HPV type form
the basis for decisions regarding which HPV types should be
included in HPV screening tests as well as in vaccines and it is
therefore important to estimate the type-specific risks using
population-based prospective studies, a study design that mini-
mises major sources of bias.
Only two previous prospective studies have assessed the risk
associated with several individual HPV types (Schiffman et al,2 0 0 5 ;
Berkhof et al, 2006), while several prospective studies have assessed
certain clusters of HPV types (Koutsky et al, 1992; Liaw et al,1 9 9 9 ;
Sherman et al, 2003; Szoke et al, 2003; Peto et al, 2004; Winer et al,
2005) or only investigated HPV types 16 and 18 (Khan et al, 2005).
Therefore, we HPV-tested a population-based cohort of women
and used a comprehensive registry-based follow-up to identify the
risks for development of histopathologically verified high-grade
cervical intraepithelial neoplasia (CIN2þ) associated with infec-
tions with 14 different so-called ‘high-risk’ HPV types.
MATERIALS AND METHODS
Cohort definition
A population-based multicentre study was started in Sweden in
May 1997 with the main purpose to evaluate the effect of HPV
testing in primary cervical cancer screening. Women aged between
32 and 38 years (mean age: 35.1 years) in five regions in Sweden
(Gothenburg, Malmo ¨, Stockholm, Umea ˚ and Uppsala) who took
part in organised cervical screening were invited to take part in the
study. Following informed consent, 12527 women were enrolled
and randomised either to action on HPV tests (6257 women) or to
no action on HPV tests (6270 women), as described in detail
elsewhere (Elfgren et al, 2005). All women had a cervical brush
sample taken at baseline that was used for routine cytological
screening and then frozen in 1ml of 0.9% NaCl for future HPV
DNA analysis. Referral to colposcopy was based on routine clinical
management. Furthermore, HPV-positive women in the interven-
tion arm that did not have an abnormal enrolment smear in
cytology and pathology registries were invited for a second HPV
test and cytology on average 19 months later and if persistently
positive invited to colposcopy. A matched number of women from
the control arm were also invited for HPV test, cytology and
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population-based cohort was formed from 6257 women in the
intervention arm as well as 409 women randomly selected from
the control arm that had HPV tests performed on their baseline
samples.
All women were followed by registry linkages using unique
personal identification numbers with both the regional cytology
and pathology registries in the enrolling regions, as well as with
the national cervical screening registry, to detect development of
CIN2þ. All women with an abnormal histopathological diagnosis
as well as all women invited for colposcopy within the study
protocol had their specimens re-evaluated by a single expert
pathologist (WR) who was masked to the HPV status of the
women. For 22 specimens that could not be located in the
pathology archives, the original diagnosis was retained. Overall,
126/148 (85%) of the CIN2þ diagnoses in the present study have
been confirmed by expert pathologist review. Women who had an
inadequate (b-globin-negative) HPV test at baseline (172 women)
or who had no cytological or histological samples registered during
follow-up (796 women) were excluded from the analysis. The final
population-based cohort thus consisted of 5696 women with a
mean follow-up time of 4.1 years.
HPV DNA testing
The virus laboratory that performed the HPV analyses was masked
to cytological and histological diagnoses of the women. Cervical
brush samples were analysed using a general HPV primer GP5þ/
6þ-mediated PCR-enzyme immunoassay consisting of a pool of
digoxigenin-labelled HPV type-specific oligonucleotide probes of
14 high-risk HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66 and 68) (de Roda Husman et al, 1995; Jacobs et al, 1997).
Human b-globin was amplified simultaneously in the PCR-EIA
assay to test for sample DNA quality. All HPV-positive samples
were typed by reverse dot blot hybridisation (RDBH) using HPV
type-specific plasmids corresponding to the different HPV types
tested for in the PCR-EIA (Forslund et al, 2002). PCR-EIA-positive
samples negative in RDBH were cloned and sequenced. Samples
were considered HPV positive only if successfully typed by RDBH
or by DNA sequencing.
Statistical analysis
Statistical analyses were performed using STATA 9.0. Absolute
cumulative risks of future CIN2þ and CIN3þ with binominal
exact 95% confidence intervals (CI) were calculated for each HPV
type. Relative rates for CIN2þ and their 95% CI were calculated
using Poisson regression. Women were censored at their last
testing date, except for women who developed CIN2þ who were
censored at the date when the diagnostic biopsy was taken. Since
lesions that were detected early during follow-up might have been
present already at baseline we split the data according to length of
follow-up of more or less than 6 months. A likelihood ratio test
was then performed to assess if there was interaction between HPV
infection and time of CIN2þ diagnosis. There was weak evidence
for interaction (P-value 0.10) and thus we adjusted for time of
diagnosis by introducing a term in the regression model
representing follow-up of more or less than 6 months. Because
the risk associated with one HPV type can be confounded by co-
infection with other HPV types, we adjusted for infection with
other HPV types by including type-specific HPV data as single
variables in a multivariate regression model. Population attribu-
table proportions were calculated as pc*(RR-1)/RR where pc is the
proportion exposed to an HPV type among cases and RR is the
type-specific relative rate adjusted for infection with other HPV
types and censoring before or after 6 months of follow-up
(Miettinen, 1974). Ninety-five percent CI for population attribu-
table proportions were calculated from the standard error of the
log-transformed complement of the population attributable
proportions [ln(1-PAF)] (Rothman and Greenland, 1998). To test
for type-specific differences of relative rates, the b-coefficients
of each HPV type in the multivariate regression model were
compared with the b-coefficient of HPV 16 by fitting a constrained
model and performing a likelihood ratio test (StataCorp, 2005).
RESULTS
During a mean follow-up time of 4.1 years, 148 women developed
CIN2þ. One hundred and twenty-seven (85.8%) of these had a
positive HPV test at baseline. The HPV type with highest
population-based prevalence of infection was HPV 16 (2.5%),
followed by type 31 (1.4%), 45 (0.9%) and 18 (0.7%). A single HPV
type was detected in 401 (87.0%) of the HPV-positive women,
while 60 (13.0%) women had more than one virus type detected in
the same sample. Most multiple HPV infections were infections
with two HPV types, but up to four different HPV types could be
detected in the same sample. The absolute risk of CIN2þ among
HPV-positive women ranged from 0% for HPV 59 to 48.0% (95%
CI: 27.8–68.7) for HPV 33 (Table 1). HPV 16 infection had an
absolute risk of future CIN2þ of 36.6% (95% CI: 28.7–45.1) and
HPV 18 infection had an absolute risk of 25.6% (95% CI: 13.0–
42.1). HPV 31 and 58 were also associated with very high absolute
risks of 36.7% (95% CI: 26.1–48.3) and 30.4% (95% CI: 13.2–52.9),
respectively (Table 1). The absolute risk of developing CIN2þ
among women infected with any high-risk HPV type was 27.5%
(95% CI: 23.5–31.9). Women who were HPV negative had a low
absolute risk of future CIN2þ (0.40% (95% CI: 0.25–0.61)). The
absolute risks for future CIN3þ were highest for HPV 16 (28.2%
(95% CI: 20.9–36.3)), HPV 33 (28.0% (95% CI: 12.1–49.4)),
HPV 31 (22.8% (95% CI: 14.1–33.6)) and HPV 58 (21.7% (95% CI:
7.5–43.7)) (Table 1).
The relative rates of CIN2þ for each HPV type were assessed
using women negative for the corresponding HPV type as the
reference group (Table 1). It should be noted that we have
deliberately avoided analyses using women who were HPV
negative for all HPV types as the reference group. Such analysis
cannot take the issue of multiple infections into account, resulting
in inflated relative rates, for example the relative rate for HPV 16
was 27.6 (19.7–38.6) (Table 1), but the HPV 16-related relative rate
would have been 118.4 (71.3–196.6) if women negative for all HPV
types had been used as a reference group.
After adjustment for concomitant infections with other HPV
types, the type-specific relative rates segregated into three groups.
HPV 16, 31 and 33 had very high relative rates (exceeding 10)
(Table 1), with all other types having significantly lower risks than
HPV 16 (Table 1). HPV types 18, 39, 51, 52, 56 and 58 conferred
significantly elevated risks for CIN2þ, with relative risks in the
range 3- to 7-fold (Table 1). We were not able to detect any excess
risk for CIN2þ associated with HPV 35, 45, 59 or 66 (Table 1).
Population attributable proportions were based on the type-
specific relative rates adjusted for all other HPV types. HPV 16
attributed to 33.1% (95% CI: 24.7–40.6) followed by HPV 31
(18.3% (95% CI: 11.5–24.5)), HPV 33 (7.7% (95% CI: 3.1–12–0))
and HPV 18 (5.7% (95% CI: 1.5–9–7)) (Table 1). HPV 35, 39, 45,
56, 59 and 66 each contributed to 2.0% or less of CIN2þ in the
population. HPV 16 and 18 together attributed to 39.0% (95% CI:
30.2–46.7) of CIN2þ and the four types (HPV 16, 18, 31, 33) that
contributed most individually jointly attributed to 64.0% (95% CI:
55.0–71.2). Overall, 84.7% (95% CI: 73.3–89.7) of CIN2þ was
attributed to an HPV infection.
DISCUSSION
This prospective large-scale study provides individual estimates of
the risk for future histopathologically confirmed high-grade CIN
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risk’ HPV tests. The large size and prospective study design, nested
within the national screening programme and our comprehensive
follow-up argue in favour of reliability of estimates.
We report that several HPV types previously classified as ‘high-
risk’ types (Munoz et al, 2003) convey significantly lower risk for
future CIN2þ compared to HPV 16. This is in line with a cohort
study in Costa Rica of 10000 women which reported HPV 16 to be
uniquely carcinogenic among ‘high-risk’ HPV types in its risk of
progression to CIN3/cancer after persistent infection (Schiffman
et al, 2005). Also, in a cohort of 20810 women in Portland, US, the
10-year cumulative incidence rate of CIN3þ among women with
a negative, equivocal, or mildly abnormal baseline cervical pap
smear was 17.2% among HPV 16-positive women, 13.6% among
HPV 18-positive women but only 3.0% among women with a
positive Hybrid Capture 2 test but negative for HPV 16 and 18 at
baseline (Khan et al, 2005). Besides HPV 16 we also found that
HPV 31 and 33 conveyed rate ratios of future CIN2þ above 10.
These results are similar to a Dutch report, where these three types
were associated with the highest risk for future CIN2þ during 18
months of follow-up (Berkhof et al, 2006).
Risk classification of genital HPV types has hitherto mostly been
based on case–control studies (Munoz et al, 2003). In a pooled
analysis of 11 case–control studies performed by IARC that
included samples from 1918 women with squamous cervical
carcinoma and 1928 controls, 15 HPV types (HPV 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82) were classified as high-
risk types and HPV 26, 53 and 66 as probably high-risk types
(Munoz et al, 2003). Even though prospective studies use high-
grade CIN as end point, which is only a surrogate for cervical
cancer, they convey important methodological advantages to
establish causal relationships. Case–control studies are not only
sensitive to reverse causality bias, but many case–control studies
sample differently from cases (biopsies) and controls (brush
samples) which might affect HPV test performance. Furthermore,
it is often difficult to obtain population-representative controls.
Therefore we believe that more robust risk classification of HPV
types can be obtained from prospective population-based studies.
Population-attributable proportions estimate the reduction in
incidence of a disease if the exposure under study was eliminated
from the population (e.g., by vaccination). The population-
attributable proportions were based on HPV type-specific relative
rates, that is the rates for a specific HPV type compared to the rate
among women negative for that HPV type (not compared to
women negative for all HPV types). This choice of reference group
is more appropriate for studying attributable proportions since the
elimination of one HPV type does not imply that the population
would become negative for all HPV types. It should be noted that
even though our type-specific relative rates as well as our
classification of which types are oncogenic differs from the
above-mentioned studies (Munoz et al, 2003), our relative rates,
if we would have used women negative for any HPV as reference
group would have been rather similar to these other studies (data
not shown).
After adjustment of our type-specific estimates for presence of
other HPV types, we found no elevated risk for future CIN2þ
among women infected with HPV 35, 45, 59 and 66. However, the
CI were large, especially for HPV 35, and it is possible that our
failure to detect any association with disease for these HPV types
may be attributable to limited statistical power. We found that the
elimination of HPV 16 would diminish the burden of CIN2þ by
33% and removal of both HPV 16 and 18 would reduce the
incidence of CIN2þ by 39% in our population of Swedish women
aged 32–38 years. It is noteworthy that both HPV 31 and 33, which
are not included in current prophylactic vaccines, both contri-
buted to more CIN2þ than did HPV 18. These four HPV types
(HPV 16, 18, 31 and 33) jointly attributed to almost 65% of all
CIN2þ, and prevention of infection with these four types would
therefore be most important. By contrast, HPV types 35, 39, 45, 56,
59 and 66 each contributed to 2.0% or less of CIN2þ in the
population and inclusion of these types in HPV vaccines therefore
seems less important, as the theoretical possibility exists that
inclusion of too many HPV types in second generation HPV
vaccines might impair the response against the most important
HPV type (i.e., HPV 16). In a cohort of 10000 women in Costa
Rica, HPV 16 was the type that contributed most to prevalent cases
of CIN3þ followed by HPV 58, 18 and 31 (Schiffman et al, 2005).
In our study, HPV 58 infection was rare in the population and
only 4% of CIN2þ cases were attributed to HPV 58. Since
population attributable proportions are dependent not only on the
Table 1 HPV type-specific risks and population attributable proportions for the development of histopathologically confirmed high-grade CIN during a
mean follow-up time of 4 years in a cohort of 5696 women
HPV type
Absolute risk of CIN2+
((95% C), CIN2+ cases/
women infected)
Absolute risk of CIN3+
((95% CI), CIN3+
cases/women infected)
Relative rate
a for
CIN 2+ (95% CI)
Relative rate
b,c for
CIN 2+ (95% CI)
Population
attributable
proportion (95% CI)
HPV negative 0.40% (0.25–0.61) 21/5235 0.19% (0.092–0.35) 10/5235 — — —
HPV 16 36.6% (28.7–45.1) 52/142 28.2% (20.9–36.3) 40/142 27.6 (19.7–38.6) 17.4 (12.0–25.1) 33.1% (24.7–40.6)
HPV 18 25.6% (13.0–42.1) 10/39 15.4% (5.9–30.5) 6/39 11.3 (6.0–21.5) 6.3 (3.1–12.5)* 5.7% (1.5–9–7)
HPV 31 36.7% (26.1–48.3) 29/79 22.8% (14.1–33.6) 18/79 20.1 (13.4–30.1) 14.9 (9.7–22.9) 18.3% (11.5–24.5)
HPV 33 48.0% (27.8–68.7) 12/25 28.0% (12.1–49.4) 7/25 27.8 (15.4–50.2) 18.5 (9.1–37.4) 7.7% (3.1–12–0)
HPV 35 9.1% (1.1–29.2) 2/22 4.5% (0.1–22.8) 1/22 4.2 (1.0–16.9) 3.1 (0.8–12.9)** 0.9% (0–2.8)
HPV 39 17.6% (3.8–43.4) 3/17 11.8% (1.5–36.4) 2/17 6.6 (2.1–20.7) 6.0 (1.9–19.4)* 1.7% (0–3.9)
HPV 45 19.2% (9.6–32.5) 10/52 7.7% (2.1–18.5) 4/52 8.3 (4.4–15.8) 0.9 (0.4–2.1)*** —
HPV 51 17.2% (5.8–35.8) 5/29 17.2% (5.8–35.7) 5/29 7.4 (3.0–18.0) 5.3 (1.9–14.7)** 2.7% (0–5.6)
HPV 52 26.1% (10.2–48.4) 6/23 13.0% (2.8–33.6) 3/23 10.9 (4.8–24.6) 4.2 (1.8–9.7)** 3.1% (0–6.3)
HPV 56 10.3% (2.9–24.2) 4/39 2.6% (0.06–13.5) 1/39 4.3 (1.6–11.7) 3.7 (1.3–10.2)** 2.0% (0–4.6)
HPV 58 30.4 (13.2–52.9) 7/23 21.7% (7.5–43.7) 5/23 13.4 (6.3–28.7) 5.9 (2.5–14.1)* 3.9% (0.4–7.3)
HPV 59 0% 0/14 0% 0 0*** —
HPV 66 7.4% (0.9–24.3) 2/27 3.7% (0.0 –19.0) 1/27 3.1 (0.8–12.4) 0.3 (0.07–1.3)*** —
HPV 68 No detected infection — — — —
HPV 16 and/or HPV 18 34.3% (27.3–41.7) (61/178) 25.3% (19.1–32.3) 45/178 27.4 (19.7–38.0) 18.9 (13.2–27.1) 39.0% (30.2–46.7)
HPV16 and/or 18 and/or 31
and/or 33
56.1% (48.3–63.6) 97/270 24.4% (19.4–30.0) 66/270 47.2 (33.6–66.2) 42.4 (29.9–60.3) 64.0% (55.0–71.2)
All HPV positives 27.5% (23.5–31.9) 127/461 18.4% (15.0–22.3) 85/461 80.8 (50.9–128.3) 80.8 (50.9–128.3) 84.7% (73.3–89.7)
aAdjusted for censoring before or after 6 months of follow-up.
bAdjusted for censoring before or after 6 months of follow-up and for other HPV types.
cType-specific relative
rates that were significantly different from HPV 16 relative rate: P-value *0.01o0.05, **0.001o0.01 and ***o0.001.
HPV type-specific risk of high-grade CIN
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it is likely that differences in type-specific prevalences of infection
in different populations account for the observed differences.
Limitations of the study include the risk of verification bias, as
women with a negative HPV test are less likely to be referred to
colposcopy and subsequently having a biopsy taken during the
course of the study. This could influence the attributable
proportion estimates but not the relative comparison of type-
specific absolute risks or risk rates. The bias of HPV-based
verification diminishes successively with increasing length of
follow-up using conventional cytology and most of the women in
the cohort were followed for more than two screening rounds (in
Sweden the screening interval is 3 years). Also, detection of
CIN2þ is exceedingly rare when HPV-negative, cytology-negative
women are referred to colposcopy suggesting that verification bias
has not materially affected our estimates (Belinson et al, 2001).
It has been suggested that CIN 3þ is a more appropriate proxy
for the risk of future cervical cancer than CIN2þ since the
regression rate is higher for CIN2 than for CIN 3 (Schiffman and
Kjaer, 2003). Although our statistical power to address CIN3þ
rates was more limited, we found similar patterns of differences in
HPV-type-specific risks.
In conclusion, we found that different so-called ‘high-risk’ HPV
types convey very different risks for future CIN2þ, with HPV 16
and its close relatives HPV 31 and 33 consistently conferring the
highest risks. Appreciation of the HPV-type-specific risks for
CIN2þ can be helpful for interpretation and design of HPV tests
as well as for second-generation vaccines against HPV.
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